Get the Stockscreener App
100.69
0.39%
0.39
Pre-market:
100.46
-0.23
-0.23%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $100.69, with a volume of 11.11M.
It is up +0.39% in the last 24 hours and down -6.79% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$100.30
Open:
$100.125
24h Volume:
11.11M
Relative Volume:
0.98
Market Cap:
$174.97B
Revenue:
$44.33B
Net Income/Loss:
$6.50B
P/E Ratio:
27.09
EPS:
3.717
Net Cash Flow:
$7.40B
1W Performance:
-1.57%
1M Performance:
-6.79%
6M Performance:
-23.36%
1Y Performance:
-20.64%
1-Day Range:
$99.05
$100.89
1-Week Range:
$99.05
$103.83
52-Week Range:
$99.05
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
100.69 | 174.29B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
347.24 | 129.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
88.00 | 111.97B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
63.18 | 91.83B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.12 | 44.90B | 6.07B | 1.06B | 1.34B | 1.8063 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Urges Toss Of Relator, State Suits In FCA Recall Row - Law360
Abbott Laboratories stock edges lower as Team Abbott spotlights runner's Boston Marathon story - Traders Union
TD Cowen reiterates Buy on Abbott Labs stock, cites Cologuard strength - Investing.com
Unlocking Q1 Potential of Abbott (ABT): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance Singapore
Abbott Laboratories to contest damages awarded in NEC infant-formula ruling - Global Food Industry News
eyeQ: M&G, easyJet, Broadcom, Abbott Labs - Interactive Investor
Abbott Infant-Formula Jury Awards $70 Million Damages - Claims Journal
Jury awards total of $70 million in damages in case against Abbott over infant formula - Times West Virginian
Abbott's Punitive Damages Precedent Risks Sentiment Mismatch With Resilient Earnings - Bitget
Abbott Laboratories (ABT) Faces $70M Damages in Baby Formula Law - GuruFocus
Abbott ordered to pay $70M in damages in Chicago baby formula case - Seeking Alpha
Bartlett & CO. Wealth Management Trims Abbott Laboratories Holdings - National Today
Abbott Laboratories Hit with $70M Verdict in Infant Formula Lawsuit - National Today
Jury orders Abbott to pay US$70mil in preterm infant formula trial - Free Malaysia Today
Abbott Laboratories to pay $70M in damages in infant formula lawsuit - Chicago Sun-Times
Jury orders Abbott to pay $70 million in preterm infant formula trial, company says - Reuters
Is Abbott Laboratories (ABT) Appealing After Recent Share Price Pullback? - Yahoo Finance
Chicago jury awards millions to families after babies fall ill after consuming Abbott Laboratories formula - ABC7 Chicago
Abbott Jury Awards at Least $53 Million in Infant-Formula Trial - Bloomberg.com
Cook County jury awards total of $70 million in damages in cases against Abbott over infant formula - Chicago Tribune
Abbott (ABT) Ordered to Pay $17M in Baby Formula Case - GuruFocus
Abbott Ordered to Pay $53 Million in NEC Baby Formula Trial as Punitive Damages Loom - Consumer Notice
Abbott Laboratories stock (US0028241000): Is diagnostics strength enough to counter nutrition pressu - AD HOC NEWS
Abbott Laboratories Stock (ABT) Moved Down by 3.04% on Apr 10: A Full Analysis - TradingKey
-3.05% for Abbott Laboratories stock as persistent selling outweighs support - Traders Union
Abbott Laboratories stock hits 52-week low at $100.85 By Investing.com - Investing.com South Africa
Abbott Laboratories stock hits 52-week low at $100.85 - Investing.com
Abbott hit with $70 million verdict in Chicago infant-formula trial - Crain's Chicago Business
Abbott Laboratories price faces negative outlookForecast today10-04-2026 - Economies.com
Abbott survey finds ‘information overload, confusion and cost’ affecting health choices in US - Fierce Pharma
Dividend Roundup: AGNC Investments, Abbott Labs, AbbVie, and more (AGNC:NASDAQ) - Seeking Alpha
Abbott Laboratories: Solid Q1 Setup and Resilient MedTech/Diagnostics Support Path to 2026 Targets Amid Manageable Geopolitical Headwinds - TipRanks
TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $137 - Moomoo
How Abbott Baby Formula Verdict and Rising Litigation Risk May Reshape Abbott Laboratories' (ABT) Investment Profile - simplywall.st
Abbott Laboratories (ABT) Ordered to Pay $53M Over Infant Formul - GuruFocus
Chicago jury orders Abbott to pay $53M in preterm infant formula trial - Seeking Alpha
ABT Technical Analysis | Trend, Signals & Chart Patterns | ABBOTT LABORATORIES (NYSE:ABT) - ChartMill
Abbott jury awards at least US$53 mil in infant-formula trial - The Edge Singapore
Jury orders Abbott to pay US$53 mil in pre-term infant formula trial, says Chicago Tribune - The Edge Malaysia
Jury orders Abbott to pay $53 million in preterm infant formula trial, media report says By Reuters - Investing.com
Abbott jury awards at least $53 million in infant-formula trial - MSN
Jury orders Abbott to pay $53 million in preterm infant formula trial, media report says - Yahoo! Finance Canada
Abbott Laboratories must pay at least $53 million in cases over infant formula, jury decides - The Daily Gazette
Could Buying This Dividend Pharma Stock Today Set You Up for Life? - The Motley Fool
Abbott Hit With $53M Verdict Over Baby Formula Harms - Law360
How The Abbott Laboratories (ABT) Investment Story Is Shifting With New Targets And Trial Updates - Yahoo Finance
Goldman Sachs Lowers Price Target for Abbott Laboratories (ABT) Today | ABT Stock News - GuruFocus
Abbott India Ltd stock: Why it's drawing global investor attention now - AD HOC NEWS
Abbott Laboratories (ABT) likely to benefit from nutrition segment recovery - MSN
Abbott (ABT) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Abbott Laboratories: A Dividend Aristocrat With A Compelling Valuation And Return Potential - Seeking Alpha
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):